Christopher G Kanakry1, Paul V O'Donnell1, Terry Furlong1, Marcos J de Lima1, Wei Wei1, Marta Medeot1, Marco Mielcarek1, Richard E Champlin1, Richard J Jones1, Peter F Thall1, Borje S Andersson1, Leo Luznik2. 1. Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX. 2. Christopher G. Kanakry, Marta Medeot, Richard J. Jones, Leo Luznik, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University School of Medicine, Baltimore, MD; Paul V. O'Donnell, Terry Furlong, Marco Mielcarek, Fred Hutchinson Cancer Research Center, Seattle, WA; Marcos J. de Lima, Wei Wei, Richard E. Champlin, Peter F. Thall, Borje S. Andersson, The University of Texas MD Anderson Cancer Center, Houston, TX. luznile@jhmi.edu.
Abstract
PURPOSE: The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies. We hypothesized that combining these two promising approaches in a multi-institutional study of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates of severe acute and chronic GVHD, low toxicity, and effective disease control. PATIENTS AND METHODS: Ninety-two adult patients (median age, 49 years; range, 21 to 65 years) with high-risk hematologic malignancies were enrolled at three centers (clinical trial No. NCT00809276). Forty-five patients received related allografts, and 47 received unrelated allografts. GVHD prophylaxis was solely with PTCy at 50 mg/kg/day on post-transplantation days +3 and +4. RESULTS: The cumulative incidences of grades 2 to 4 acute, grades 3 to 4 acute, and chronic GVHD were 51%, 15%, and 14%, respectively. Nonrelapse mortality (NRM) at 100 days and 1 year were 9% and 16%, respectively. With a median follow-up period of 2.2 years, the 2-year disease-free survival (DFS) and overall survival (OS) rates were 62% and 67%, respectively. Donor relatedness did not affect NRM, DFS, or OS. Patients in complete remission (CR) without evidence of minimal residual disease (MRD) had markedly better DFS (80%) and OS (80%) than patients in CR with MRD or with active disease at the time of transplantation (DFS, P = .0005; OS, P = .019). CONCLUSION: This multi-institutional study demonstrates that PTCy can be safely and effectively combined with IV Bu/Flu myeloablative conditioning and confirms PTCy's efficacy as single-agent, short-course GVHD prophylaxis for both acute and chronic GVHD after bone marrow transplantation from HLA-matched donors.
PURPOSE: The clinical safety and efficacy of intravenous busulfan and fludarabine (IV Bu/Flu) myeloablative conditioning as well as graft-versus-host disease (GVHD) prophylaxis with high-dose, post-transplantation cyclophosphamide (PTCy) have been demonstrated independently in several single-institutional studies. We hypothesized that combining these two promising approaches in a multi-institutional study of human leukocyte antigen (HLA) -matched bone marrow transplantation would provide low rates of severe acute and chronic GVHD, low toxicity, and effective disease control. PATIENTS AND METHODS: Ninety-two adult patients (median age, 49 years; range, 21 to 65 years) with high-risk hematologic malignancies were enrolled at three centers (clinical trial No. NCT00809276). Forty-five patients received related allografts, and 47 received unrelated allografts. GVHD prophylaxis was solely with PTCy at 50 mg/kg/day on post-transplantation days +3 and +4. RESULTS: The cumulative incidences of grades 2 to 4 acute, grades 3 to 4 acute, and chronic GVHD were 51%, 15%, and 14%, respectively. Nonrelapse mortality (NRM) at 100 days and 1 year were 9% and 16%, respectively. With a median follow-up period of 2.2 years, the 2-year disease-free survival (DFS) and overall survival (OS) rates were 62% and 67%, respectively. Donor relatedness did not affect NRM, DFS, or OS. Patients in complete remission (CR) without evidence of minimal residual disease (MRD) had markedly better DFS (80%) and OS (80%) than patients in CR with MRD or with active disease at the time of transplantation (DFS, P = .0005; OS, P = .019). CONCLUSION: This multi-institutional study demonstrates that PTCy can be safely and effectively combined with IV Bu/Flu myeloablative conditioning and confirms PTCy's efficacy as single-agent, short-course GVHD prophylaxis for both acute and chronic GVHD after bone marrow transplantation from HLA-matched donors.
Authors: Asad Bashey; Xu Zhang; Connie A Sizemore; Karen Manion; Stacey Brown; H Kent Holland; Lawrence E Morris; Scott R Solomon Journal: J Clin Oncol Date: 2013-02-19 Impact factor: 44.544
Authors: Jennifer A Kanakry; Yvette L Kasamon; Javier Bolaños-Meade; Ivan M Borrello; Robert A Brodsky; Ephraim J Fuchs; Nilanjan Ghosh; Douglas E Gladstone; Christopher D Gocke; Carol Ann Huff; Christopher G Kanakry; Leo Luznik; William Matsui; Huzefa J Mogri; Lode J Swinnen; Heather J Symons; Richard J Jones; Richard F Ambinder Journal: Biol Blood Marrow Transplant Date: 2013-07-18 Impact factor: 5.742
Authors: Marcelo C Pasquini; Steven Devine; Adam Mendizabal; Lindsey R Baden; John R Wingard; Hillard M Lazarus; Frederick R Appelbaum; Carolyn A Keever-Taylor; Mary M Horowitz; Shelly Carter; Richard J O'Reilly; Robert J Soiffer Journal: J Clin Oncol Date: 2012-08-06 Impact factor: 44.544
Authors: Roland B Walter; Sarah A Buckley; John M Pagel; Brent L Wood; Barry E Storer; Brenda M Sandmaier; Min Fang; Boglarka Gyurkocza; Colleen Delaney; Jerald P Radich; Elihu H Estey; Frederick R Appelbaum Journal: Blood Date: 2013-07-11 Impact factor: 22.113
Authors: Christopher G Kanakry; Sudipto Ganguly; Marianna Zahurak; Javier Bolaños-Meade; Christopher Thoburn; Brandy Perkins; Ephraim J Fuchs; Richard J Jones; Allan D Hess; Leo Luznik Journal: Sci Transl Med Date: 2013-11-13 Impact factor: 17.956
Authors: Orly R Klein; Allen R Chen; Christopher Gamper; David Loeb; Elias Zambidis; Nicolas Llosa; Jeffrey Huo; Amy E Dezern; Diana Steppan; Nancy Robey; Mary Jo Holuba; Kenneth R Cooke; Heather J Symons Journal: Biol Blood Marrow Transplant Date: 2016-02-06 Impact factor: 5.742
Authors: Amin M Alousi; Jonathan E Brammer; Rima M Saliba; Borje Andersson; Uday Popat; Chitra Hosing; Roy Jones; Elizabeth J Shpall; Issa Khouri; Muzaffar Qazilbash; Yago Nieto; Nina Shah; Sairah Ahmed; Betul Oran; Gheath Al Atrash; Stefan Ciurea; Partow Kebriaei; Julianne Chen; Gabriela Rondon; Richard E Champlin Journal: Biol Blood Marrow Transplant Date: 2015-02-07 Impact factor: 5.742
Authors: Christopher G Kanakry; Javier Bolaños-Meade; Yvette L Kasamon; Marianna Zahurak; Nadira Durakovic; Terry Furlong; Marco Mielcarek; Marta Medeot; Ivana Gojo; B Douglas Smith; Jennifer A Kanakry; Ivan M Borrello; Robert A Brodsky; Douglas E Gladstone; Carol Ann Huff; William H Matsui; Lode J Swinnen; Kenneth R Cooke; Richard F Ambinder; Ephraim J Fuchs; Marcos J de Lima; Borje S Andersson; Ravi Varadhan; Paul V O'Donnell; Richard J Jones; Leo Luznik Journal: Blood Date: 2017-01-03 Impact factor: 22.113
Authors: S Garciaz; L Castagna; R Bouabdallah; S Fürst; S Bramanti; D Coso; R Crocchiolo; J El-Cheikh; F Broussais; C Chabannon; A Santoro; D Blaise Journal: Bone Marrow Transplant Date: 2015-03-02 Impact factor: 5.483
Authors: Nahid Rashid; Michael Slade; Ramzi Abboud; Feng Gao; John F DiPersio; Peter Westervelt; Geoffrey Uy; Keith Stockerl-Goldstein; Rizwan Romee; Mark A Schroeder Journal: Transpl Int Date: 2020-06-19 Impact factor: 3.782
Authors: Erica Dahl Warlick; Todd E DeFor; Nelli Bejanyan; Shernan Holtan; Margaret MacMillan; Bruce R Blazar; Kathryn Dusenbery; Mukta Arora; Veronika Bachanova; Sarah Cooley; Aleksandr Lazaryan; Philip McGlave; Jeffrey S Miller; Armin Rashidi; Arne Slungaard; Gregory Vercellotti; Celalettin Ustun; Claudio Brunsein; Daniel Weisdorf Journal: Biol Blood Marrow Transplant Date: 2018-08-01 Impact factor: 5.742
Authors: Burak Kalin; Yvette van Norden; Michel van Gelder; Dimitri Breems; Johan Maertens; Mojca Jongen-Lavrencic; Annoek E C Broers; Eric Braakman; Tim Grob; Wendelien Zeijlemaker; Gert J Ossenkoppele; Ellen Meijer; Jan J Cornelissen Journal: Blood Adv Date: 2020-09-22
Authors: Shannon R McCurdy; Stephen T Muth; Hua-Ling Tsai; Heather J Symons; Carol Ann Huff; William H Matsui; Ivan Borrello; Douglas E Gladstone; Lode J Swinnen; Kenneth R Cooke; Robert A Brodsky; Javier Bolaños-Meade; Richard F Ambinder; Ravi Varadhan; Leo Luznik; Richard J Jones; Maria P Bettinot; Ephraim J Fuchs Journal: Biol Blood Marrow Transplant Date: 2018-06-15 Impact factor: 5.742
Authors: J De La Serna; J Sanz; A Bermúdez; M Cabrero; D Serrano; C Vallejo; V Gómez; J M Moraleda; S G Perez; M D Caballero; E Conde; J J Lahuerta; G Sanz Journal: Bone Marrow Transplant Date: 2016-03-07 Impact factor: 5.483